ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2021

Jul 1, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Ken Taylor

Date of last notice 8 July 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct
Nature of indirect interest(including registered holder)Note:Providedetailsofthecircumstances giving rise to the relevantinterest.
Date of change		1 July 2021
No. of securities held prior tochange		Unlisted options	Exercise Price	Expiry Date
		250,000	$0.100	01-Jul-21
		100,000	$0.190	01-Jul-21
		250,000	$0.0487	13-Dec-21
		Total 600,000
Class		Unlisted Options
Number acquired		Nil
Number disposed		350,000 unlisted options
Value/ConsiderationNote: If consideration is non-cash,provide details and estimated valuation		N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	No. of securities held afterchange						Expiry Date13-Dec-21
			Unlisted options		Exercise Price		Expiry Date
			250,000		$0.0487		13-Dec-21
			Total 250,000
	Nature of changeExamle: on-market trade off-market		E	xpiry of unlisted options as detaile		d above.
	p ,trade, exercise of options, issue ofsecurities under dividend reinvestmentplan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Detail of contract	Detail of contract	Detail of contract	N/A	N/A	N/A	N/A	N/A
	Nature of in	terest
	Name of registered holder(if issued securities)
	Date of change
	No. and class of securities to		which
	interest related prior to changeNt Dtil l id f tt		i lti
	oe: eas are ony requre or a conracto which the interest has changed		n reaon
	Interest acquired
	Interest disposed
	Value/ConsiderationNote: If consideration is non-cash, provide det		ails and an
	estimated valuation
	Interest after change

Part 3 –[+] Closed period

Part 3 –+Cl	Part 3 –+Cl	osed period
	Were the iabove trad	nterests in the sed during a+clos	curities or contraed period where	cts detailedprior written	No
	clearance w	as required?
	If so was p	rior written cleara	nce provided to all	ow the trade
	,to proceed
		uring this period?
	If prior writt
		en clearance was	rovided, on what	ate was this
	provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011